Results 131 to 140 of about 17,321,273 (254)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy

Vascular Health and Risk Management, 2008
Kalathil K SureshkumarDivision of Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, Pennsylvania, USAAbstract: Hypertension is a major risk factor for the development of cardiovascular and renal disease.
Kalathil K Sureshkumar
doaj  

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Correlation of serum chloride concentrations with components of the renin‐angiotensin‐aldosterone system in a dog with congestive heart failure

Journal of Veterinary Internal Medicine
A 7‐year‐old male castrated Cavalier King Charles Spaniel was hospitalized for 12 days for treatment of severe congestive heart failure secondary to myxomatous mitral valve disease.
Cailey Banken, Autumn N. Harris, Rachel Conway, Eduardo J. Benjamin, Robin Shoemaker, Darcy Adin   +5 more
doaj   +1 more source

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, EarlyView.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

Beyond the circulating renin angiotensin aldosterone system

Frontiers in Endocrinology, 2014
Walmor eDe Mello
doaj   +1 more source

Aldosterone, aldosterone receptor blockers and chronic kidney disease

Zdravniški Vestnik, 2011
Chronic kidney disease (CKD) is a worldwide public health problem and an important risk factor for cardiovascular events, morbidity and mortality. The renin-angiotensin-aldosteron system (RAAS) drugs, angiotensin-converting enzyme inhibitors and/or ...
Sebastjan Bevc
doaj  

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar, Luxcia Kugathasan, Manon Girard, Michael J. Davies, David Z. I. Cherney   +4 more
wiley   +1 more source

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

Obesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed, Juan S. Barajas‐Gamboa, Mohammad Zubaid, Ebaa Al Ozairi, Abdullah Shehab, Khalid Al‐Rasadi, Charbel Abi Khalil, Noor Al Busaidi, Fahad Al Sindi, Zuhier Awan, Tomader Ali, Khaldoon Al‐Humood, Fatheya Al Awadi, Mohammed Al Hadad, Manal Al Kindi, Khalid Al Habib, Khalid Al Waili, Maryam Alsaeed, Adel Tash, Hani Sabbour   +19 more
wiley   +1 more source